、医保谈判开启，看好创新药及产业链机会医药生物-医药生物行业周报证券研究报告/行业周报2023年11月19日评级：增持（维持）[重Ta点bl公e_司Fi基na本nc状e]况分析师：祝嘉琦公司名称股价EPSPEPEG评级执业证书编号：S0740519040001电话：021-2031515020222023E2024E2025E20222023E2024E2025E1.48买入Email：zhujq@zts.com.cn3.24买入分析师：崔少煜迈瑞医疗285.507.929.E5311.4713.7936.0329.9524.8820.710.93买入执业证书编号：S07405220600010.730.881.0576.9864.4753.7944.851.36买入Email：cuisy@zts.com.cn恒瑞医药47.140.613.314.215.4028.7525.8220.2815.800.64买入1.311.652.1045.4836.1028.5622.511.14买入药明康德85.362.973.784.716.0620.4917.0313.6610.621.30买入0.961.241.6644.4435.4327.5320.601.5...